scPharmaceuticals Inc. (SCPH): Price and Financial Metrics


scPharmaceuticals Inc. (SCPH): $7.12

-0.21 (-2.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SCPH Stock Price Chart Interactive Chart >

Price chart for SCPH

SCPH Price/Volume Stats

Current price $7.12 52-week high $7.96
Prev. close $7.33 52-week low $3.48
Day low $7.12 Volume 403,400
Day high $7.70 Avg. volume 156,223
50-day MA $5.83 Dividend yield N/A
200-day MA $5.33 Market Cap 195.33M

scPharmaceuticals Inc. (SCPH) Company Bio


scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.


SCPH Latest News Stream


Event/Time News Detail
Loading, please wait...

SCPH Latest Social Stream


Loading social stream, please wait...

View Full SCPH Social Stream

Latest SCPH News From Around the Web

Below are the latest news stories about SCPHARMACEUTICALS INC that investors may wish to consider to help them evaluate SCPH as an investment opportunity.

scPharmaceuticals Announces Pricing of $50 Million Public Offering

BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 6,620,000 shares of its common stock at a public offering price of $5.25 per share and, to an investor in lieu of common stock, a prefunded warr

Yahoo | November 22, 2022

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock (the “Offering”). All Shares to be sold in the Offering will be offered by scPharmaceuticals. The Offering is sub

Yahoo | November 21, 2022

Analysts’ Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), scPharmaceuticals (SCPH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report), scPharmaceuticals (SCPH – Research Report) and Processa Pharmaceuticals (PCSA – Research Report) with bullish sentiments. Jazz Pharmaceuticals (JAZZ) Jefferies analyst Akash Tewari maintained a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $185.00. The company's shares closed last Wednesday at $140.00. According to TipRanks.

Howard Kim on TipRanks | November 10, 2022

SVB Securities Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)

SVB Securities analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals (SCPH - Research Report) today and set a price target of $12.00. The company's shares closed yesterday at $5.38.Ruiz covers the Healthcare sector, focusing on stocks such as scPharmaceuticals, Pardes Biosciences, and Amarin. According to TipRanks, Ruiz has an average return of -46.4% and a 12.77% success rate on recommended stocks. Currently, the analyst consensus on scPharmaceuticals is a Strong Buy with an average price target of $14.00, a 160.22% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

Austin Angelo on TipRanks | November 10, 2022

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Entered into a secured debt financing agreement for up to $100 million with funds managed by Oaktree Capital Continued to advance commercial readiness activities in support of upcoming FUROSCIX commercial launch planned in Q1 2023 Company to host inaugural investor call and webcast today, November 9

Yahoo | November 9, 2022

Read More 'SCPH' Stories Here

SCPH Price Returns

1-mo 32.10%
3-mo 21.92%
6-mo 52.14%
1-year 66.36%
3-year 60.00%
5-year -57.06%
YTD 41.83%
2021 -5.10%
2020 -6.54%
2019 50.53%
2018 -68.90%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7703 seconds.